HANSOH PHARMA ANNOUNCES XINYUE(INEBILIZUMAB) PRIORITY REVIEW GRANTED BY NMPA FOR THE TREATMENT OF IGG4-RD
On February 10, 2025, Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) , a leading innovation-driven pharmaceutical company in China, t...
2025.02.10